Article Information
History
- September 26, 2020.
Article Versions
- Version 1 (September 8, 2020 - 02:00).
- Version 2 (September 8, 2020 - 09:42).
- Version 3 (September 25, 2020 - 11:24).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Manuel Rubio-Rivasa,*,
- Jose María Mora-Lujána,
- Abelardo Monteroa,
- Narcís A. Homsa,
- Jordi Rellob,c,d and
- Xavier Corbellaa,d
- aDepartment of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, Barcelona, Spain
- bCentro de Investigación Biomédica en Red (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- cCRIPS, Vall d’Hebrón Institute of Research, Barcelona, Spain
- dSchool of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain
- ↵*Corresponding author
: Dr Manuel Rubio-Rivas, Internal Medicine Department, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain. E-mail addresses: mrubio{at}bellvitgehospital.cat (M. Rubio-Rivas)
J. Rello and X. Corbella contributed equally as last authors
Posted September 26, 2020.
Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis
